The historical rank and industry rank for Ono Pharmaceutical Co's ROE % or its related term are showing as below:
TSE:4528'
s ROE % Range Over the Past 10 Years
Min: 6.35 Med: 10.97 Max: 16.68
Current: 8.61
During the past 13 years, Ono Pharmaceutical Co's highest ROE % was 16.68%. The lowest was 6.35%. And the median was 10.97%.
TSE:4528's ROE % is ranked better than 60.24% of 933
companies
in the Drug Manufacturers industry
Industry Median: 5.89
vs TSE:4528: 8.61
Ono Pharmaceutical Co (TSE:4528) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Ono Pharmaceutical Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ono Pharmaceutical Co ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ono Pharmaceutical Co's ROE % distribution charts can be found below:
* The bar in red indicates where Ono Pharmaceutical Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Ono Pharmaceutical Co (TSE:4528) has a ROE % of 0.39% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Ono Pharmaceutical Co and its competitors. This is 96% below median its historical median of 10.97. Over the past decade, Ono Pharmaceutical Co's ROE % has ranged from 6.35 to 16.68. According to the industry distribution chart, Ono Pharmaceutical Co ranks #371 out of 933 companies in the Drug Manufacturers industry, placing it in the top 39.8%.
Is Ono Pharmaceutical Co's ROE % too high?
Ono Pharmaceutical Co's current ROE % of 0.39% is 96% below median its 10-year median of 10.97. Over the past 10 years, this metric has ranged from a low of 6.35 to a high of 16.68. The Drug Manufacturers industry median ROE % is 5.89. Ono Pharmaceutical Co's value of 0.39% is 93.4% below this industry median. Based on the distribution chart, Ono Pharmaceutical Co ranks #371 out of 933 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ono Pharmaceutical Co has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ono Pharmaceutical Co's ROE % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Ono Pharmaceutical Co ranks #371 out of 933 companies for ROE %. This puts Ono Pharmaceutical Co in the upper half of its industry. The industry median ROE % is 5.89. Ono Pharmaceutical Co's value of 0.39% is 93.4% below this benchmark. Historically, Ono Pharmaceutical Co's own ROE % has ranged from 6.35 to 16.68 over the past decade. While the company's 10-year median is 10.97 vs. the industry median of 5.89, Ono Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.89, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ono Pharmaceutical Co's current ROE % of 0.39% is 93.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Ono Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ono Pharmaceutical Co's current ROE % is 0.39%, which is 96% below median its own 10-year median of 10.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ono Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ono Pharmaceutical Co (TSE:4528) is currently considered Fairly Valued. The stock's GF Value™ is 円2,255.53, compared to a current price of 円2,377.50 — trading 5.4% above its estimated fair value. The current ROE % is 0.39%, which is 96% below median its 10-year median of 10.97 and 93.4% below the Drug Manufacturers industry median of 5.89. Ono Pharmaceutical Co's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Ono Pharmaceutical Co (TSE:4528), the current ROE % is 0.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ono Pharmaceutical Co (TSE:4528) Overvalued in 2026?
Based on GuruFocus' analysis, Ono Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円2,377.50 is trading 5.4% above its estimated GF Value™ of 円2,255.53.
GuruFocus considers Ono Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4528:
ROE %: 0.39% (96% below median its 10-year median of 10.97)
GF Value™: 円2,255.53 vs. price of 円2,377.50 (5.4% above fair value)
Industry Position: 93.4% below the Drug Manufacturers median (#371 of 933)
No single metric tells the full story. See the TSE:4528 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The vast majority of the company's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe.
88GF Score
Get the complete analysis for TSE:4528
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4528 has been successfully added to your 
